HOME >> MEDICINE >> NEWS
NOVANTRONE application for multiple sclerosis granted priority review by FDA

FDA review of NOVANTRONE data to be completed within six months

SEATTLE-Immunex Corporation (NASDAQ:IMNX) announced today that the U.S. Food and Drug Administration (FDA) has assigned priority review status to the new drug application (NDA) for NOVANTRONER (mitoxantrone for injection concentrate), indicating that the FDA will act on the application within six months of its date of submission. Immunex filed for expanded labeling for NOVANTRONE for the treatment of patients with secondary progressive multiple sclerosis (MS) on June 7, 1999.

"This is an important milestone in the development of NOVANTRONE as a potential treatment for people with secondary progressive MS," said Peggy V. Phillips, senior vice president, pharmaceutical development for Immunex. "We will continue to work closely with the FDA over the next six months as they evaluate these data."

The results of the pivotal NOVANTRONE Phase III study showed that NOVANTRONE had a statistically significant impact on reduction of relapse rate and delay in disability progression in patients with secondary progressive MS. Additional follow-up data presented at a recent international conference showed that one year after treatment was stopped, patients treated with NOVANTRONE continued to experience a reduction in their number of attacks, and a delay in their disability progression.

In the study, treatment with NOVANTRONE resulted in generally manageable side effects that were primarily mild to moderate. During the two-year trial, the most frequent side effects reported by patients treated in the 12 mg/m2 arm were nausea, alopecia (hair loss), upper respiratory tract infection, urinary tract infection, menstrual disorder, and transient neutropenia (a reduced number of white blood cells).

Multiple sclerosis is a chronic, debilitating disease of the central nervous system that, in its various stages, afflicts as many as 350,000 people in the Unit
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
19-Jul-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Considerable reductions in radiation exposure possible with 16-MDCT scanner on body applications
3. AstraZeneca submits regulatory application in Europe for use of Atacand(R) in heart failure
4. Roche files marketing application for Avastin with European health authorities
5. ENBREL application for early, active rheumatoid arthritis filed with the U.S. Food and Drug Administration
6. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
7. Research suggests possible blood test for multiple sclerosis
8. Mayo Clinic researchers announce promising next generation treatments for multiple myeloma
9. Good fats decrease multiple heart disease risk factors
10. Swallowing multiple magnets poses danger to children
11. Sleep disorders often indicate multiple health conditions

Post Your Comments:
(Date:5/24/2015)... 24, 2015 ProPin is a set ... Pro X. Utilize ProPin to pin point locations on a ... , ProPin allows users to choose from 30 simplistic ... With on-screen controls, video editors can easily manipulate ProPin presets ... and mark with absolute ease. , Using ProPin is easy, simply ...
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 volunteers ... Florida City exactly five years to the day after the ... A large fire tore through the Branches United Methodist Church ... the middle of the night as neighbors, staff and Branches' ... even though it is suspected that the fire began accidentally. ...
(Date:5/23/2015)... Parker, CO (PRWEB) May 23, 2015 On ... participated in MuckFest. The event was a 5k mud obstacle ... affects more than 2 million people worldwide, and the reason ... our community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. ... National Multiple Sclerosis Society.” , The event was not only ...
(Date:5/23/2015)... 23, 2015 Injury lawyer Steven H. Heisler ... passed by the Maryland legislature but which has not been ... Assembly passed HB 449 with overwhelming bipartisan support ... signed it into law. This bill ensures that fracking is ... that demonstrates the danger of fracking to our water supplies ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board of ... Chief Financial Officer (CFO), will be leaving the organization ... company CFO since 2011. , The Board of Trustees ... system as CFO. Wesley will oversee the health system’s ... of Trustees conducts a formal search for a replacement. ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2
(Date:5/22/2015)... May 22, 2015 Electrophysiologist Kevin Makati, ... traveled to Boston, MA ... 2015 Heart Rhythm Society conference. These scientific sessions ... on the ideas, people and technology that propel ... a hybrid, minimally invasive cardiac operation that combines ...
(Date:5/22/2015)... 22, 2015  The U.S. Food and Drug ... the first biosimilar product approved in ... growth in the contract manufacturing organization (CMO) industry, ... is geared to the production of small-molecular drugs ... products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... According to a new market ... Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020", published by ... reach $736.85 Million by 2020 from $452.36 Million in ... Browse 71 market data Tables and 90 Figures ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
Cached News: